

PREFERRED EXTENDED RELEASE STIMULANTS

Applies To:

amphetamine-dexamphetamine extended release capsule (ADDERALL XR)
 methylphenidate extended release tablet (CONCERTA)
 methylphenidate extended release capsule (RITALIN LA)
 lisdexamfetamine capsule (VYVANSE)
 lisdexamfetamine chewable tablet (VYVANSE)

Diagnoses Considered for Coverage:

- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Binge Eating Disorder – *Vyvanse only*

Coverage Criteria:

1. **For patients less than 18 years of age:** no prior authorization required, quantity limits apply.
2. **For diagnosis listed above and 18 years of age or older:**
 - Dose does not exceed FDA label maximum dose, **and**
 - Total dosage has been consolidated to the least number of higher strength dosage forms (e.g. tablets), **and**
 - One of the following:
 - Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner with mental health specialty), **or**
 - Being used for narcolepsy confirmed by a positive sleep study (polysomnography), **or**
 - Being used for compendia or guideline supported diagnosis and for psychiatric conditions - diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty).

Coverage Duration: one year

References:

1. Adderall XR [package insert]. Lexington, MA: Takeda Pharmaceuticals USA Inc.; February 2022.
2. Concerta [package insert]. Titusville, NJ: Janssen Pharmaceuticals; June 2021.
3. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; June 2021.
4. Vyvanse [package insert]. Lexington, MA: Takeda Pharmaceuticals USA Inc.; February 2022

Effective Date: 3/1/2023